OURS is re-imagining and de-stigmatizing couples therapy. Photo by Mikhail Nilov/Pexels

A Houston startup that's re-imagining mental health treatment and counseling has emerged from stealth, announcing financial support from seed investors including tennis legend and venture capital investor Serena Williams.

Targeting the $5 trillion health and wellness market, OURS is founded by family therapist and author Liz Earnshaw, as well as Adam Putterman and Jessica Holton.

“We’re excited to take this first step in shifting the way we think about relationship health. We are building for a world that treats relationship health with equal importance as physical, mental and emotional health. We want working on your relationships to be an everyday experience, accessible to all,” says Holton, who serves as co-CEO, in a news release.

The company has raised nearly $5 million pre-seed and seed round from investors including TMV, Serena Ventures, Lakehouse Ventures, Collaborative Fund, GreyMatter, and pioneering angel investors such as Andy Dunn.

“Research shows that relationships are the most important factor to our overall health and wellbeing, which is an area that I'm hyper-focused on in my personal life,” says Williams, managing partner of San Francisco-based Serena Ventures, in the release. “When I learned about what the team was doing, I knew this was something we needed to support.

"OURS offers a reimagined and preventative solution to relationship wellness that's not only experiential and research-backed, but memorable and fun," she continues. "We're proud to be early investors in a brand that is making relationship health accessible to couples everywhere and play an integral part of the larger OURS mission.”

OURS has thousands of couples already using its platform. Image via OURS

The company launched its beta in 2020 and has already worked with thousands of customers and has an engaged community of couples across its platforms.

The OURS founders were inspired by their own experiences with couples counseling and created a technology-enabled platform based of expert and data-backed research.

“As it stands, the current mental health and wellness space is largely geared towards individuals, yet nearly 50 percent of couples have either participated in, or have sought out solutions, to foster stronger romantic partnerships,” says Soraya Darabi, co-founder and general partner at TMV, in the release. “However, a lack of therapists - until now - or confused perception of couples counseling leave needs unmet.”

Initially targeting romantic partners, the platform costs $400 for a four-week program that includes six personalized interactive sessions with an OURS guide at the helm of the experience. These one-hour technology-powered sessions are based around an innovative new technology, called Loveware, and include dynamic and meaningful conversations between a couple that are built around the magic that comes from being in the room with an expert.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”

Chevron enters the lithium market with major Texas land acquisition

to market

Chevron U.S.A., a subsidiary of Houston-based energy company Chevron, has taken its first big step toward establishing a commercial-scale lithium business.

Chevron acquired leaseholds totaling about 125,000 acres in Northeast Texas and southwest Arkansas from TerraVolta Resources and East Texas Natural Resources. The acreage contains a high amount of lithium, which Chevron plans to extract from brines produced from the subsurface.

Lithium-ion batteries are used in an array of technologies, such as smartwatches, e-bikes, pacemakers, and batteries for electric vehicles, according to Chevron. The International Energy Agency estimates lithium demand could grow more than 400 percent by 2040.

“This acquisition represents a strategic investment to support energy manufacturing and expand U.S.-based critical mineral supplies,” Jeff Gustavson, president of Chevron New Energies, said in a news release. “Establishing domestic and resilient lithium supply chains is essential not only to maintaining U.S. energy leadership but also to meeting the growing demand from customers.”

Rania Yacoub, corporate business development manager at Chevron New Energies, said that amid heightening demand, lithium is “one of the world’s most sought-after natural resources.”

“Chevron is looking to help meet that demand and drive U.S. energy competitiveness by sourcing lithium domestically,” Yacoub said.

---

This article originally appeared on EnergyCapital.